IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas

被引：0
|
作者：
Li, K. [1 ]
Kotturi, M. F. [2 ]
Manlusoc, M. [3 ]
Yun, R. [1 ]
Hinton, P. R. [1 ]
Logronio, K. [2 ]
Baliga, R. [4 ]
Hernandez, G. [5 ]
Sinclair, A. M. [3 ]
Carroll, S. F. [2 ]
Godfrey, W. R. [6 ]
Keyt, B. A. [7 ]
机构：
[1] IGM Biosci, Antibody Discovery, Mountain View, CA USA
[2] IGM Biosci, Preclin Sci, Mountain View, CA USA
[3] IGM Biosci, Immunooncol, Mountain View, CA USA
[4] IGM Biosci, Discovery Biol, Mountain View, CA USA
[5] IGM Biosci, Clin Biomarkers, Mountain View, CA USA
[6] IGM Biosci, Clin Dev Clin Stats & Regulatory, Mountain View, CA USA
[7] IGM Biosci, Res & Dev, Mountain View, CA USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
841P
引用
收藏
页码：S778 / S779
页数：2
相关论文
共 50 条
  • [31] Comparative in-Vitro Efficacy of CD20xCD3 IgG Bispecific Biosimilar Constructs Against Diffuse Large B Cell Lymphoma (DLBCL) Cell Lines with Different Levels of Expression of CD20
    Bray, Joshua S.
    Thomas, Gethin R.
    Smith, Victoria M.
    Jayne, Sandrine
    Dyer, Martin J. S.
    Walter, Harriet S.
    BLOOD, 2024, 144 : 5826 - 5827
  • [32] CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies
    Martyniszyn, Alexandra
    Krahl, Ann-Christin
    Andre, Maya C.
    Hombach, Andreas A.
    Abken, Hinrich
    HUMAN GENE THERAPY, 2017, 28 (12) : 1147 - 1157
  • [33] Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster
    Li, Huafei
    Zhang, Ge
    Jiang, Cheng
    Zhang, Fulei
    Ke, Changhong
    Zhao, He
    Sun, Yun
    Zhao, Mengxin
    Chen, Di
    Zhu, Xiandi
    Zhang, Li
    Li, Bohua
    Dai, Jianxin
    Li, Wei
    ONCOTARGET, 2015, 6 (27) : 24192 - 24204
  • [34] UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma
    Caracciolo, Daniele
    Polera, Nicoletta
    Belmonte, Beatrice
    Conforti, Francesco
    Signorelli, Stefania
    Gulino, Alessandro
    Staropoli, Nicoletta
    Tuccillo, Franca Maria
    Bonelli, Patrizia
    Juli, Giada
    Grillone, Katia
    Ascrizzi, Serena
    Cirillo, Maria
    Migale, Leonardo
    Ballerini, Andrea
    Pelizon, Cristina
    Di Martino, Maria Teresa
    Tagliaferri, Pierosandro
    Riillo, Caterina
    Tassone, Pierfrancesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (02) : 555 - 560
  • [35] THE DIAGNOSTIC CHALLENGE OF RITUXIMAB-INDUCED CD20 NEGATIVE B-CELL LYMPHOMAS
    Risser, J.
    Breen, C.
    Feder, S.
    O'Leary, E.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2011, 38 (01) : 159 - 159
  • [36] Novel bispecific antibodies in CD20-positive B-cell non-Hodgkin lymphomas
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (SUPPL 6) : 137 - 138
  • [37] A Novel CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Effects Against B Cell Lymphoma in Mice
    Varghese, Bindu
    Menon, Jayanthi
    Rodriguez, Luis
    Haber, Lauric
    Olson, Kara
    Duramad, Paurene
    Oyejide, Adelekan
    Smith, Eric
    Thurston, Gavin
    Kirshner, Jessica
    BLOOD, 2014, 124 (21)
  • [38] Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20xCD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
    Brouwer-Visser, Jurriaan
    Fiaschi, Nathalie
    Deering, Raquel P.
    Cygan, Kamil J.
    Scott, Darius
    Jeong, Se
    Boucher, Lauren
    Gupta, Namita T.
    Gupta, Suraj
    Adler, Christina
    Topp, Max S.
    Bannerji, Rajat
    Duell, Johannes
    Advani, Ranjana H.
    Flink, Dina M.
    Chaudhry, Aafia
    Thurston, Gavin
    Ambati, Srikanth R.
    Jankovic, Vladimir
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [39] Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
    Liu, Yanlong
    Ao, Kexin
    Bao, Fuxiang
    Cheng, Yi
    Hao, Yanxia
    Zhang, Huimin
    Fu, Shan
    Xu, Jiaqi
    Wu, Qiyao
    VACCINES, 2022, 10 (08)
  • [40] Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies
    Zurko, Joanna C.
    Xu, Huiqing
    Chaney, Katherine
    Schneider, Dina
    Szabo, Aniko
    Hari, Parameswaran
    Johnson, Bryon D.
    Shah, Nirav N.
    CYTOTHERAPY, 2022, 24 (08) : 767 - 773
12345